Biogen (NasdaqGM: BIIB), Celgene (NasdaqGM: CELG), Gilead (NasdaqGM: GILD) and Amgen (NasdaqGM: AMGN) combine for about a third of IBB’s weight. As a double-leveraged ETF, BIS can pack a punch. That much is affirmed by its almost 13% gain since last Friday and IBB’s three-month volatility of nearly 21%.
When biotech is out of favor, however briefly, BIS can really move. The sector struggled a bit around this time last year. BIS proceed to surge 27% from mid-October through November 8, 2012.
ProShares UltraShort Nasdaq Biotechnology
ETF Trends editorial team contributed to this post.